Beigene, Ltd. (NASDAQ:ONC) Receives $319.00 Consensus Target Price from Analysts

Shares of Beigene, Ltd. (NASDAQ:ONCGet Free Report) have been assigned an average rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $319.00.

ONC has been the topic of several recent analyst reports. Guggenheim lifted their price objective on Beigene from $348.00 to $350.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Sanford C. Bernstein set a $259.00 target price on Beigene in a research note on Thursday, March 13th. Bank of America upgraded Beigene from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd. JPMorgan Chase & Co. upped their price objective on Beigene from $311.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, April 21st. Finally, Royal Bank of Canada dropped their price objective on Beigene from $312.00 to $311.00 and set an “outperform” rating on the stock in a research note on Thursday, May 8th.

View Our Latest Report on ONC

Beigene Price Performance

NASDAQ:ONC opened at $269.63 on Friday. Beigene has a fifty-two week low of $141.31 and a fifty-two week high of $287.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The company has a market cap of $29.52 billion, a PE ratio of -32.72, a PEG ratio of 7.73 and a beta of 0.30. The company’s 50-day simple moving average is $241.38.

Beigene (NASDAQ:ONCGet Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of ($0.71) by $1.93. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.12 billion. On average, research analysts expect that Beigene will post -5.82 earnings per share for the current year.

Insider Transactions at Beigene

In related news, insider Xiaodong Wang sold 41,760 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $261.28, for a total transaction of $10,911,052.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Titus B. Ball sold 134 shares of the business’s stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $258.36, for a total value of $34,620.24. The disclosure for this sale can be found here. Insiders have sold a total of 228,258 shares of company stock worth $58,317,119 in the last 90 days. Corporate insiders own 6.62% of the company’s stock.

Beigene Company Profile

(Get Free Report

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

Featured Stories

Analyst Recommendations for Beigene (NASDAQ:ONC)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.